Kiadis Pharma « Terug naar discussie overzicht

Molmed versus Kiadis Pharma en aanverwante biotech aandelen

722 Posts, Pagina: « 1 2 3 4 5 6 ... 32 33 34 35 36 37 | Laatste
MG76
0
Overname bod op molmed van 0.518 euro

Japan's AGC launches bid on Italy's Molmed worth up to 240 mln euros
Contributor
3-4 minuten

Published

Mar 17, 2020 3:18AM EDT

Japan's AGC has launched a takeover bid on all the shares of Italian biotech company Molmed in a deal worth up to 240 million euros ($267 million), AGC said in a statement on Tuesday.

MILAN, March 17 (Reuters) - Japan's AGC 5201.T has launched a takeover bid on all the shares of Italian biotech company Molmed MLMD.MI in a deal worth up to 240 million euros ($267 million), AGC said in a statement on Tuesday.

AGC is offering 0.518 euros per Molmed share, the equivalent of a premium of 110.3%.

AGC said Fininvest, the holding company of the family of former Prime Minister Silvio Berlusconi, had agreed to tender its stake in Molmed.

Fininvest owns around 23% of Molmed shares.

The aim of the bid is to delist Molmed, AGC said.
[verwijderd]
0
722 Posts, Pagina: « 1 2 3 4 5 6 ... 32 33 34 35 36 37 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
923,71  0,00  0,00%  07 jun
 Germany40^ 18.547,30 -0,05%
 BEL 20 3.900,39 0,00%
 EURO50 5.042,41 0,00%
 US30^ 38.783,90 0,00%
 Nasd100^ 18.997,40 0,00%
 US500^ 5.344,04 0,00%
 Japan225^ 38.664,30 0,00%
 Gold spot 2.296,43 +0,12%
 EUR/USD 1,0750 -0,22%
 WTI 75,26 0,00%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

AALBERTS NV 0,00%
ABN AMRO BANK... 0,00%
Accsys 0,00%
ACOMO 0,00%
ADYEN NV 0,00%

Dalers

AALBERTS NV 0,00%
ABN AMRO BANK... 0,00%
Accsys 0,00%
ACOMO 0,00%
ADYEN NV 0,00%

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront